Kryxana 200mg Tablet

Metastatic ​Breast Cancer

Most side effects of Kryxana 200mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

• Seizures  
• Vomiting  
• Diarrhea  
• Chest tightness  
• Stomach pain  
• Nausea 
• Unusual tiredness  
• Itching 
• Changed sense of taste
• Trouble sleeping
• Headache
• Decreased white blood cell count
• Back pain
• Tingling of hands and feet

• Take Kryxana 200mg Tablet in exact dose as prescribed by the doctor.
• The typical dose of this tablet varies with age, type & stage of the cancer, and overall health factor of the patient.
• It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule.
• Don't miss a dose or overdose the medicine.

Kryxana 200mg Tablet is an anticancer medicine with active ingredient Ribociclib (200mg). It belongs to a group of cancer-fighting medications known as antineoplastics.

This tablet works by blocking the action of the kinase protein, which is important for the growth and division of cells. As a result, it slows the progression of cancer.

​If you forget to take a dose of Kryxana Tablet, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Abdelmalak, M., Singh, R., Anwer, M., et al. (2022). The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance. Cancers, 14(21), 5388 - https://pubmed.ncbi.nlm.nih.gov/36358806/

Dajsakdipon, T., Susiriwatananont, T., Wongkraisri, C., Ithimakin, S., Parinyanitikul, N., Supavavej, A., & TSCO Breast Oncology Group. (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus aromatase inhibitor in HR+/HER2− advanced breast cancer: Preliminary real‑world data from Thailand. BMC Cancer, 24(1), 1018 - https://link.springer.com/article/10.1186/s12885-024-12765-x

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., … Goetz, M. P. (2022). Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine, 386(18), 942–950 - https://pubmed.ncbi.nlm.nih.gov/35263519/

Ji, Y., Yartsev, V., Quinlan, M., Serra, P., Wang, Y., Chakraborty, A., & Miller, M. (2023). Justifying ribociclib dose in patients with advanced breast cancer with renal impairment based on PK, safety, and efficacy data: An innovative approach integrating data from a dedicated renal impairment study and oncology clinical trials. Clinical Pharmacokinetics, 62(3), 493–504 - https://pubmed.ncbi.nlm.nih.gov/36800111/

Xu, J., Wang, R., & Shen, K. (2025). A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System. Therapeutic Advances in Drug Safety, 16, 20420986251324633 - https://pmc.ncbi.nlm.nih.gov/articles/PMC11869255/